Loading...
XNASTRIB
Market cap2mUSD
Dec 23, Last price  
0.90USD
1D
12.13%
1Q
-28.24%
Jan 2017
-87.04%
Name

Trinity Biotech PLC

Chart & Performance

D1W1MN
XNAS:TRIB chart
P/E
—
P/S
0.18
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.14%
Rev. gr., 5y
-10.15%
Revenues
57m
-24.00%
79,944,00098,560,000118,674,000143,617,000140,139,000125,907,00089,635,00077,948,00082,510,00091,216,000104,871,000100,195,00099,611,00099,140,00097,035,00090,435,000101,980,00092,965,00074,779,00056,832,000
Net income
-24m
L-41.42%
5,166,0005,280,0003,276,000-35,372,000-77,778,00011,824,00060,418,00015,593,00017,341,00010,337,00017,213,00021,796,000-100,626,000-40,270,0002,390,000-4,066,000-6,013,000875,000-41,002,000-24,018,000
CFO
-12m
L+1,154.83%
42,0009,209,0007,368,00015,349,00010,729,00014,732,00023,073,00020,484,00020,056,00011,706,00015,752,00012,335,00013,771,00012,112,0006,935,0005,474,00023,755,00013,238,000-921,000-11,557,000
Dividend
Jun 05, 20150.22 USD/sh
Earnings
Jan 29, 2025

Profile

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
URL
https://www.trinitybiotech.com/
IPO date
Oct 21, 1992
Employees
398
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
56,832
-24.00%
74,779
-19.56%
92,965
-8.84%
Cost of revenue
41,761
56,869
84,068
Unusual Expense (Income)
NOPBT
15,071
17,910
8,897
NOPBT Margin
26.52%
23.95%
9.57%
Operating Taxes
(59)
(192)
(178)
Tax Rate
NOPAT
15,130
18,102
9,075
Net income
(24,018)
-41.42%
(41,002)
-4,785.94%
875
-114.55%
Dividends
Dividend yield
Proceeds from repurchase of equity
25,336
BB yield
-1,316.64%
Debt
Debt current
1,904
210
85,292
Long-term debt
78,089
71,990
29,710
Deferred revenue
(13,865)
Other long-term liabilities
526
13,836
13,865
Net debt
76,088
65,410
88,941
Cash flow
Cash from operating activities
(11,557)
(921)
13,238
CAPEX
(803)
(5,977)
(8,691)
Cash from investing activities
24,756
(5,977)
(8,691)
Cash from financing activities
(16,042)
(12,322)
(6,019)
FCF
21,315
25,024
14,098
Balance
Cash
3,691
6,578
25,910
Long term investments
214
212
151
Excess cash
1,063
3,051
21,413
Stockholders' equity
(45,646)
(30,421)
8,416
Invested Capital
89,650
100,310
90,002
ROIC
15.93%
19.02%
9.75%
ROCE
32.55%
23.90%
8.61%
EV
Common stock shares outstanding
7,655
7,775
5,326
Price
0.11
-56.67%
0.25
-30.77%
0.36
-62.47%
Market cap
821
-57.34%
1,924
1.06%
1,904
-52.18%
EV
76,909
67,334
90,845
EBITDA
16,847
20,243
11,641
EV/EBITDA
4.57
3.33
7.80
Interest
10,148
24,745
5,459
Interest/NOPBT
67.33%
138.16%
61.36%